SenzaGen wins innovation prize SKAPA and is appointed as provincial finalist

SenzaGen has won yet another award and was recently appointed the provincial finalist in Skåne and will thereby have the opportunity to win the national innovation award SKAPA, the country’s largest and most prestigious innovation prize. The SKAPA Prize is awarded to innovators in order to support the commercialization of their products.

The prize is awarded by the Foundation SKAPA in cooperation with ALMI. It is the regional ALMI companies in cooperation with local inventors’ associations affiliated to the Swedish Inventors Association which has chosen the county finalists for the award.

The appointment means that SenzaGen have the opportunity to be appointed Swedish champion of innovation. As the county finalist, SenzaGen receives a prize worth SEK 25 000 with the option to gain an additional SEK 550 000 (maximum spread over three laureates) if they succeed as winners of the national prize.

– SenzaGen has been able to package advanced research in a transparent, commercial way and have in a short time shown that they will be able to both significantly minimize the number of animal tests  being performed and deliver a better accuracy in the tests and hence a better value to their customers. It is going to be very exciting to follow the company in the future! says Johan Olsen, ALMI

The national final is being held on 5 Nov 2015 in Stockholm.

senzagen member of the board

Ian Kimber joins the board of SenzaGen AB

SenzaGen AB, a diagnostic spin-off company from Lund University, is proud to announce that Prof. Ian Kimber will join the Board of Directors.

SenzaGen AB is a diagnostic company working to replace animal testing for sensitization predictions.

Prof Ian Kimber is currently Professor of Toxicology and Associate Dean for Business Development in the Faculty of Life Sciences at the University of Manchester. He has broad research interests at the interface between toxicology and immunology, with a particular focus on allergy and inflammation.  Professor Kimber holds, and has held, a variety of positions on national and international expert and scientific advisory committees. Currently these include the following:  Member UK Medicines and Healthcare products Regulatory Agency (MHRA) Committee for Safety of Devices, Programme Advisor Food Standards Agency Food Allergy and Intolerance Research Programme, and member MRC Translational Research Group. Professor Kimber was previously President of the British Toxicology Society (BTS) (2012-2014), and Chairman of the Board of the UK National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) (2008-2013).  

“I am delighted to be joining the Board of SenzaGen at such an exciting period of growth. Since our initial studies that led to the development and ultimate validation of the Local Lymph Node Assay I have maintained a keen interest in chemical allergy and in the development of novel approaches for improved hazard identification and risk assessment. In this respect harnessing fully the opportunities afforded by developments in the biomedical sciences is critical, and the work of SenzaGen in exploiting a genomic approach to pathway analysis and risk assessment is at the cutting edge of new developments”, says Prof Kimber.

Ian Kimber has published over 600 research papers, review articles and book chapters, and serves currently on the editorial boards of toxicology, immunology, dermatology and pathology journals.

“We are very happy to have Prof Kimber on board in SenzaGen”, since he is one of the forerunners in sensitization testing, says Prof Carl Borrebaeck, “his knowledge and interest in the field of allergy and replacement of animal testing with new technologies is very important to us. We value his participation in developing the next generation tests.”


Press release in pdf

SenzaGen one of the five most praised companies in Swedish business media

SenzaGen one of the five most praised companies at Ny Teknik & Affärsvärldens big Inovation Event for the 33 most promising young innovativ companies in Sweden.

The final ceremony for the 33-list was held in Stockholm were the hottest new technology companies in Sweden were presented. The list is presented without ranking but five companies were elected for special attention and SenzaGen was awarded a prize from ALMI, a strategic partner and SenzaGen given investment money for further development of the company.

Anki Malmborg Hager, CEO of SenzaGen features in film about the company from the event.
Film  (in Swedish)

About the 33-list
The 33-list is based on nominations by companies from all over Sweden and the winners are appointed jointly by the editorial staff of the NyTeknik and Affärsvärlden. The jury looks for companies with a unique product or service based around a clear innovation with great international potential – an innovation that has the potential to change the rules of the game in their industry. To make it on the list must now be based in Sweden up to 7 years old. For more information, visit http://www.33-listan.se

SenzaGen AB, a diagnostic spin-off company from Lund University, reports the launch of a new product for respiratory sensitization testing

SenzaGen AB is a diagnostic company working to replace animal testing for sensitization predictions.

“Sensitization through the lung is a growing issue and methods to predict if a chemical has a sensitization effect are limited”, says Anki Malmborg Hager, CEO in SenzaGen. Based on extensive research about the responses of the immune system in allergic reactions, SenzaGen has now launched a test that predicts the respiratory sensitization ability of chemicals based on the GARD methodology.

An international scientific article about the underlying research has been published in PLOS ONE, under the title “Prediction of Chemical Respiratory Sensitizers Using GARD, a Novel In vitro Assay Based on a Genomic Biomarker Signature”. http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0118808

SenzaGen´s first product, a skin sensitization test of chemicals, is already on the market.

Press release in pdf


Ny Teknik & Affärsvärlden list SenzaGen AB as one of the 33 most promising young innovative companies in Sweden.

SenzaGen rated one of Sweden´s most promising companies
On Tuesday, SenzaGen AB achieved a position on the so called 33-list in Sweden.
After several interviews by the organisers, a challenging questioning by an initiated jury and a smashing elevator pitch, Senzagen acquired a position on the renowned 33-list.

The 33-list is based on propositions of companies from all over Sweden and the winners are chosen collectively by the editorial staff at the two journals Ny Teknik and Affärsvärlden. The jury is looking for companies with a unique product or service based on a clear innovation with great international potential – an innovation with the ability to change the rules in the business. To qualify for a position on the list, the company must be based in Sweden and be less than 7 years. Read more on http://www.33-listan.se

Link to the article in Ny Teknik 2015, March 2: http://www.nyteknik.se/33listan/article3889772.ece

SenzaGen AB completes successful collaboration with Beiersdorf AG.

SenzaGen AB, a diagnostic spin-off company from Lund University, reports the successful completion of a collaboration with Beiersdorf.

SenzaGen AB, a diagnostic company working to replace animal testing, has been collaborating with Beiersdorf to evaluate its skin sensitization test for chemicals.

SenzaGen AB is based on research at the Department of Immunotechnology at Lund University, providing animal-free, in vitro sensitization tests for the cosmetic, chemical, pharmaceutical and food industries.

Beiersdorf has been working in the development and recognition of alternative methods for more than 20 years and is one of the main players in the cosmetic industry in Europe. An industry that is highly interested in recommendations in this field – especially after the ban in March 2013 on animal testing in the cosmetic industry.

“It has been very valuable for SenzaGen to be able to challenge its skin sensitization test in an industrial setting.” says Prof. Carl Borrebaeck, chairman of the board of SenzaGen.

In the collaboration, blind testing of two industrial test sets of chemicals were performed using the SenzaGen proprietary GARD assay, resulting in an accuracy of 89%.

Lund university

SenzaGen AB attracts financial support from LU Innovation System AB.

LU Innovation System AB (LUIS) has since 1999 been involved in spinning out 69 companies based on research from Lund University. The portfolio has now increased by the investment in SenzaGen AB.

“We have a strong connection to Lund University and the investment by LUIS acknowledges our work and provides us with the ability to take the next important steps in our commercialization strategy,” says Anki Malmborg Hager, CEO of SenzaGen AB.

“We are very pleased of being a partner in Senzagen, which we believe has a great commercial potential. The fact that their technology can replace animal experiments doesn´t make it worse”, says Linus Wiebe, Innovation Director Lund University and CEO LU Innovation System.

The company´s first product, a skin sensitization test of chemicals, is already on the market, and the company is working on next generation products that will address other types of sensitizers and other routes of exposure. Based on the demand from the market the company is now gearing up its commercial operations and prepares for the launch of further products.

For more information please contact:
Anki Malmborg Hager, CEO, SenzaGen AB
+46 768 284822

Linus Wiebe, Director of Innovation, LU Innovation Systems AB
0733- 451 240

henrik johansson senior scientist

Dr. Henrik Johansson, scientist and COO of SenzaGen AB, was awarded the LUSH Young Researcher Award 2014.

“The project for which Dr. Johansson was awarded, the Lush Prize Young Researcher Award, describes the development and use of the novel test method GARD – Genomic Allergen Rapid Detection, an assay for assessment of chemical sensitizers.

…GARD utilises an in vitro model of so-called dendritic cells, a central player in the human immune system. These cells are stimulated with any substances to be tested, and following an incubation time of 24h, the genetic material of the cells are isolated. By measurements of a certain set of genes in the cells, which could be viewed as on/off-switches of the immune response, the eventual risk of the tested substances ability to induce allergy can be predicted.” [Lush Prize Young Researcher http://www.lushprize.org/2014-prize/2014-prize-winners/]

Read more on Lush Prize Young Researcher Award web site

ann gidner Carl henric

SenzaGen recruits Dr. Carl-Henric Nilsson and Ann Gidner to the Board of Directors

-We are entering into a very exciting commercial phase and are happy to be able to engage board members with international experience from our target markets, says Prof. Carl Borrebaeck, chairman of the board of SenzaGen.

Carl-Henric Nilsson holds a PhD and M.Sc. in Industrial management, and is Associate Professor at Lund University, School of Economics and Management. He is CEO of Kunskapspartner AB, Chairman of Kunskapspartner Holding AB, Boardmember in FX International AB and Boffins Holding AB. Carl-Henric’s research is focused on Business development and Industrialization with numerous scientific publications. Carl-Henric is working with entrepreneurs on a global basis with a broad contact net, especially in China and the United States.

Ann Gidner holds a Master of Science in Chemical Engineering /Bioprocessing and a Bachelor in Business Administration. She has extensive international experience from the chemical industry with global leading positions in e.g. Cambrex and Lanxess Corporations. Furthermore, she has held managing positions in RFR Solutions AB, Semcon Caran AB, and Monocl AB. She is currently Director of Sales & Business Development Europe at Novozymes Biopharma, Copenhagen.

Other members of the board are chairman Carl Borrebaeck and deputy Malin Lindstedt.

For more information please contact:
Anki Malmborg Hager, CEO, SenzaGen AB
+46 768 284822

ceo senzagen anki malmborg hager

SenzaGen recruits Dr. Anki Malmborg Hager as CEO

We are very happy to have been able to recruit Dr. Malmborg, who has extensive experience from commercialization of academic results, financial markets and business developments says Prof.Carl Borrebaeck, chairman of the Board of SenzaGen.

Anki Malmborg Hager has more than 20 years´ experience in both pharmaceutical and biotech companies that are spin-offs from the University. She held the position as Investment Director in Lund University Bioscience AB between 2009 and 2011 as well as management positions in eg. Alligator Bioscience AB, XImmune AB (CEO), Cantargia AB (CEO), and Diaprost AB (CEO).

“I am very pleased to have been offered this opportunity” says Anki Malmborg Hager. “The underlying research in SenzaGen is world class and the market window of opportunity is timely and very exciting. I am looking forward to joining the SenzaGen team and to lead the next steps in the commercialization of many years of first-class research”.

For more information please contact:
Carl Borrebaeck, Chairman of the Board, SenzaGen AB
+46 708 218330